SecurityFMC / FMC Corp. (302491303)
CEO, President, Chairman of BdBRONDEAU PIERRE R
Form 4 Count430
Form 8-K Count81
Form 5 Count39
Form SC 13G/A Count30

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to FMC Corp.


DateFormTitle
2018-06-26 11-K FMC / FMC Corp. 11-K
2018-05-21 8-K FMC / FMC Corp. FORM 8-K (Current Report)
2018-05-21 8-K FMC / FMC Corp. FORM 8-K (Current Report)
2018-05-03 10-Q FMC / FMC Corp. 10-Q (Quarterly Report)
2018-05-02 8-K FMC / FMC Corp. 8-K (Current Report)
2018-04-27 8-K FMC / FMC Corp. 8-K (Current Report)
2018-04-04 DEFA14A FMC / FMC Corp. FMC CORP - DEFA14A
2018-03-29 8-K FMC / FMC Corp. 8-K (Current Report)
2018-03-16 DEF 14A FMC / FMC Corp. FMC CORP - DEF 14A
2018-03-09 8-K FMC / FMC Corp. FORM 8-K (Current Report)
2018-02-28 10-K FMC / FMC Corp. 10-K (Annual Report)
2018-02-15 SC 13G/A FMC / FMC Corp. / GLENVIEW CAPITAL MANAGEMENT, LLC - 3G/A (Passive Investment)
2018-02-16 SC 13G/A FMC / FMC Corp. / GLENVIEW CAPITAL MANAGEMENT, LLC - 3G/A (Passive Investment)
2018-02-13 SC 13G FMC / FMC Corp. / FMR LLC / Fidelity - 3G (Passive Investment)
2018-02-13 SC 13G FMC / FMC Corp. / FMR LLC / Fidelity - 3G (Passive Investment)
2018-02-12 8-K FMC / FMC Corp. 8-K (Current Report)
2018-02-09 SC 13G/A FMC / FMC Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)
2018-02-09 SC 13G/A FMC / FMC Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)
2018-01-29 SC 13G/A FMC / FMC Corp. / BlackRock Inc. - 3G/A (Passive Investment)
2018-01-29 SC 13G/A FMC / FMC Corp. / BlackRock Inc. - 3G/A (Passive Investment)
2018-01-09 8-K/A FMC / FMC Corp. 8-K/A (Current Report)
2017-11-07 10-Q FMC / FMC Corp. FORM 10-Q (Quarterly Report)
2017-11-06 8-K FMC / FMC Corp. 8-K (Current Report)
2017-11-02 8-K FMC 8-K (Current Report/Significant Event)
2017-08-02 S-8 FMC S-8 FMC CORPORATION INCENTIVE COMPENSATION AND STOCK PLAN
2017-08-02 10-Q FMC FORM 10-Q (Quarterly Report)
2017-08-01 8-K FMC FORM 8-K (Current Report/Significant Event)
2017-06-14 8-K FMC 8-K (Current Report/Significant Event)
2017-06-13 11-K FMC 11-K
2017-05-19 8-K/A FMC FORM 8-K/A (Current Report/Significant Event)
2017-05-03 10-Q FMC FORM 10-Q (Quarterly Report)
2017-05-02 8-K FMC FORM 8-K (Current Report/Significant Event)
2017-05-02 8-K FMC FORM 8-K (Current Report/Significant Event)
2017-04-28 8-K FMC FORM 8-K/A (Current Report/Significant Event)
2017-04-27 8-K FMC FORM 8-K (Current Report/Significant Event)
2017-04-10 DEFA14A FMC FMC CORP - DEFA14A
2017-04-10 SC 13G/A FMC 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-04-10 SC 13G/A FMC 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-04-04 8-K FMC FORM 8-K (Current Report/Significant Event)
2017-03-31 8-K FMC FORM 8-K (Current Report/Significant Event)
2017-03-28 DEFA14A FMC DEFA14A
2017-03-17 DEF 14A FMC FMC CORPORATION - DEF 14A
2017-03-10 SC 13G/A FMC SC 13G/A (Passive Acquisition of More Than 5% of Shares)
2017-03-10 SC 13G/A FMC SC 13G/A (Passive Acquisition of More Than 5% of Shares)
2017-03-29 10-K FMC 10-K (Annual Report)
2017-02-14 SC 13G/A FMC 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-14 SC 13G/A FMC 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-13 SC 13G/A FMC 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-13 SC 13G/A FMC SC 13G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-13 SC 13G/A FMC 3G/A (Passive Acquisition of More Than 5% of Shares)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 302491303